SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Denver, CO.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Palantir is trending as a report surfaced regarding security flaws in a battlefield communication system, triggering a sharp sell-off despite the company's rebuttal and claims that the issues were resolved. The community is debating the severity and validity of the report, with some viewing it as a buying opportunity while others express concerns about the company's valuation. Discussions also involve the potential impact on government contracts and the trustworthiness of news sources.

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers Health is trending amid discussions around Novo Nordisk's potential entry into the telehealth space with an obesity pill, which could impact HIMS' market share, while others are pointing out that weightloss is only a small part of the business. The community is debating whether this news presents a buying opportunity or signals a concerning shift in the competitive landscape, especially since some are looking at the COO exit as a negative catalyst. Some traders are noting technical levels and expressing frustration with the stock's volatile price action and seeming sensitivity to news.

Luckin Coffee, Inc. engages in providing food and beverage items, and operates coffee retail stores. It has a pioneered a technology-driven retail network to provide coffee and other products of high quality, high convenience and high affordability to customers. The company manages pick-up stores, relax stores, and delivery kitchens. It also offers tea, snacks, and light meals through its mobile application. The company was founded by Zhi Ya Qian, Fei Yang and Jin Yi Guo on June 16, 2017 and is headquartered in Xiamen, China.

Luckin Coffee Inc - ADR

Luckin Coffee is trending as investors discuss its potential U.S. expansion and speculate on a possible Nasdaq relisting, with community members pointing to strong fundamentals driving the stock. The company's growth in China, coupled with Starbucks' struggles, is fueling optimism, while others remain cautious due to past accounting issues and the stock's OTC status.

Rigetti Computing, Inc. provides full-stack quantum computing services. It serves global enterprise, government, and research clients through its Rigetti Quantum Cloud Services platform. The company was founded by Chad Rigetti in 2013 and is headquartered in Berkeley, CA.

Rigetti Computing Inc

RGTI is trending as retail investors and traders discuss its impressive recent gains and potential for future growth within the quantum computing sector. Community members are weighing the possibility of a short squeeze against concerns of overvaluation and a potential offering, while some highlight a recent purchase order announcement. The stock's momentum is drawing attention, with debates swirling around its long-term prospects compared to others in the quantum computing space.

Archer Aviation, Inc. engages in the development of electric vertical take-off and landing (eVTOL) aircraft. The company was founded by Brett Adcock and Adam Goldstein on October 16, 2018, and is headquartered in San Jose, CA.

Archer Aviation Inc - Ordinary Shares - Class A

Archer Aviation Inc

Archer Aviation ($ACHR) is trending amid high trading volume and anticipation surrounding potential catalysts, including upcoming airshows and FAA certification progress. The community is actively discussing the possibility of a short squeeze, as well as potential partnerships, with some drawing attention to Tesla's presence in a recent promotional video. Discussions also involve comparisons to sector peer Joby Aviation, with some traders anticipating $ACHR closing the market cap gap.

Meta Platforms, Inc. engages in the development of social media applications. It builds technology that helps people connect and share, find communities, and grow businesses. It operates through the Family of Apps (FoA) and Reality Labs (RL) segments. The FoA segment consists of Facebook, Instagram, Messenger, WhatsApp, and other services. The RL segment includes augmented, mixed and virtual reality related consumer hardware, software, and content. The company was founded by Mark Elliot Zuckerberg, Dustin Moskovitz, Chris R. Hughes, Andrew McCollum, and Eduardo P. Saverin on February 4, 2004, and is headquartered in Menlo Park, CA.

Meta Platforms Inc - Ordinary Shares - Class A

Meta Platforms Inc

META is trending as investors debate its AI spending and monetization strategies, highlighted by a recent report on AI chatbots exploring ad revenue. Community chatter reflects concerns about its recent price action, with some viewing it as a buying opportunity while others express bearish sentiment. Broader discussions include Meta's competition in the AI and AR spaces, particularly around its smart glasses.

USA Rare Earth, Inc. is domestic supplier of rare earth magnets and heavy rare earth elements. It is developing a vertically integrated, domestic supply chain for rare earth element magnet production, with a facility in Stillwater, Oklahoma, and mining rights to the Round Top heavy rare earth and critical minerals deposit in West Texas. The company was founded in May 2019 and is headquartered in Stillwater, OK.

USA Rare Earth Inc. - Ordinary Shares - Class A

USA Rare Earth Inc

USA Rare Earth (USAR) is trending due to speculation surrounding potential US government investment, fueled by the CEO's confirmation of White House discussions; the community is debating the significance of these talks and comparing USAR to other rare earth companies like MP Materials and LAC. Some investors are concerned about potential dilution from share unlocks and insider selling, while others remain optimistic about USAR's role in securing a domestic rare earth supply chain amid increasing geopolitical tensions.

C3.ai, Inc. engages in the provision of enterprise artificial intelligence software for digital transformation. It delivers the C3 AI suite for developing, deploying, and operating large-scale AI, predictive analytics, and Internet of Things applications in addition to a portfolio of turn-key AI applications. It operates through the following geographical segments: North America, Europe, The Middle East, and Africa, Asia Pacific, and Rest of World. The company was founded by Thomas M. Siebel, Patricia A. House and Stephen Maurice Ward, Jr. on January 8, 2009 and is headquartered in Redwood City, CA.

C3.ai Inc - Ordinary Shares - Class A

C3.ai Inc

C3.ai is trending amid speculation of a potential buyout, with community members pointing to increased volume and options activity as possible indicators. Chatter suggests that a big tech company could be interested in acquiring the AI firm to bolster its own AI capabilities. Despite recent financial results and leadership changes, the stock is seeing increased interest.

Clene, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology therapeutics. It offers a nanotechnology drug platform for the development of a new class of orally administered neurotherapeutic drugs. The company was founded in 2013 and is headquartered in Salt Lake City, UT.

Clene Inc

CLNN is trending as community members discuss the potential for accelerated approval of its ALS treatment following positive commentary from the FDA. Conversations revolve around the company's cash flow, potential offerings, and the possibility of a data leak driving the recent price movement. Some investors express excitement and relief, while others remain cautious due to past experiences and the need for further positive developments.

Alto Neuroscience, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of psychiatric drugs. Its pipeline is composed of five clinical-stage assets which initially target depressive disorder and schizophrenia population. The company was founded by Amit Etkin, Dan Segal, and Wei Wu on March 25, 2019 and is headquartered in Mountain View, CA.

Alto Neuroscience Inc.

Alto Neuroscience is trending amid community discussion around a potential short squeeze and recent gains. Some traders cite the company's fundamentals, upcoming data readouts, and potential for a large upside. Others remain cautious, pointing to past trial failures and ongoing discussions about a possible offering.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Shares of Protara Therapeutics Inc. skyrocketed over 100% on Thursday afternoon, reaching levels last seen in January 2022 amid a trading volume over 540 times the daily average.The clinical-stage company unveiled promising results from its ongoing Phase 2 ADVANCED-2 trial for its investigational cell-based therapy, TARA-002.The trial evaluates TARA-002 for high-risk Non-Muscle Invasive Bladder Cancer (NMIBC) in patients with carcinoma in situ (CIS) who are either Bacillus Calmette-Guérin (BCG)-Unresponsive or BCG-Naive. Highlights from the study include:• A complete response (CR) rate of 72% at six months and 70% at any time during the trial.• 100% of patients with CR at three months maintained it through six months.• Two out of three patients maintained a CR at nine months.Adverse events were generally mild, with no discontinuations due to treatment-related side effects. The most common issues, such as flu-like symptoms or bladder irritation, were consistent with responses to bacterial immunotherapy and typically resolved within hours or days.The data will be presented during a poster session at the 25th Annual Meeting of the Society of Urologic Oncology in Dallas, Texas, the company said."We are thrilled with these positive six-month data, which reinforce TARA-002's potential in NMIBC, while offering a compelling product profile for physicians and patients," said Jesse Shefferman, Chief Executive Officer of Protara Therapeutics.&nbsp;"We believe these encouraging data together with our international site expansion will accelerate patient enrollment, and we look forward to reporting initial data from 12-month evaluable patients in mid-2025."<figure class="image"><img style="aspect-ratio:1318/318;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2024_12_05_at_11_12_34_PM_c755be6fcf.png" alt="Screenshot 2024-12-05 at 11.12.34 PM.png" width="1318" height="318"><figcaption>TARA sentiment and message volume on Dec 5 as of 12:30 am ET | source: Stocktwits</figcaption></figure>Retail sentiment for TARA turned ‘extremely bullish’ on Stocktwits, with the ticker trending in the top 10 symbols by Thursday afternoon.&nbsp;<stembedurl>https://stocktwits.com/eXpeditor/message/595247480</stembedurl>Retail chatter on the stock has increased by 2,100% over the past year, with follower count growing by nearly 4%.Protara shares have surged almost 230% year-to-date, significantly outperforming broader market indices.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Retail chatter on Protara has increased by 2,100% over the past year, with follower count growing by nearly 4%.

Protara Therapeutics Stock Doubles On Promising Bladder Cancer Trial Data: Retail Buzz Spikes

The data will be presented during a poster session at the 25th Annual Meeting of the Society of Urologic Oncology in Dallas, Texas, the company said.

Equity

The data will be presented during a poster session at the 25th Annual Meeting of the Society of Urologic Oncology in Dallas, Texas, the company said.


12 titres de soins de sant  en mouvement lors de la pr -ouverture le 05/04/2024

Gagnants
Le titre Etao International Co (NASDAQ:ETAO) a mont vendredi de 25,61% 3,58 dollars lors de la session pre-market.
Le titre Protara Therapeutics (NASDAQ:TARA) a augment de 21,39% 4,88...

Protara Therapeutics announces $45M private placement financing

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

12 titoli sanitari in movimento, pre-market del 05/04/2024

Titoli in rialzo
Le azioni di Protara Therapeutics (NASDAQ:TARA) hanno fatto segnare +29,35% a 5,20 dollari durante la sessione pre-market di venerd .
Il titolo Etao International Co (NASDAQ:ETAO) ha...

12 acciones de salud en movimiento durante la preapertura del 05/04/2024

Acciones al alza
Etao International Co (NASDAQ:ETAO) experimentaron un repunte del 25,61% para establecerse en los 3,58 d lares durante la sesi n del pre-market del viernes.
Protara Therapeutics...

Protara Therapeutics Announces Oversubscribed $45 Million Private Placement Financing

Anticipated net proceeds, along with existing cash and cash equivalents, expected to extend cash runway into 2026NEW YORK, April 05, 2024 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq...

Protara Therapeutics Announces Alignment with FDA on Registrational Path Forward for IV Choline Chloride in Patients Dependent on Parenteral Nutrition

New development pathway significantly expands addressable patient population for IV Choline ChlorideIV Choline Chloride has the potential to become the first FDA-approved IV formulation of choline...

Protara Therapeutics Announces Positive Three-Month Data from TARA-002 Clinical Program in NMIBC

TARA-002 demonstrated a complete response rate of 43% at three months in BCG-Unresponsive/Experienced patients in ongoing NMIBC programTARA-002 demonstrated a complete response rate of 63% at three...

Buy Rating on Protara Therapeutics Backed by Promising TARA-002 Clinical Trials and Significant Market Opportunity

In a report released today, Stacy Ku from TD Cowen maintained a Buy rating on Protara Therapeutics (TARA Research Report), with a price target of...

Protara Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Preliminary results from ADVANCED-1EXP trial evaluating TARA-002 in NMIBC patients with CIS on track for 1H 2024Preliminary data from ADVANCED-2 trial evaluating TARA-002 in NMIBC patients with...

Protara Therapeutics, Inc. is a clinical-stage company engaged in developing treatments for rare and specialty diseases with significant unmet needs. Its current development programs focus on the treatment of rare diseases in structural and connective tissues and rare hepatology, gastrointestinal, and metabolic disorders. The company was founded by Jesse Shefferman and Jacqueline Zummo in March 2006 and is headquartered in New York, NY.

Protara Therapeutics Inc

Will PepsiCo ($PEP) beat quarterly earnings? 
 
*Powered by Polymarket

Stocktwits

PepsiCo Inc

) beat quarterly earnings? 
 
*Powered by Polymarket

Fiscal Period	Estimated	Reported	Surprise	Result
Q3 '25	-$0.38	--	--	N/A
Q2 '25	-$0.38	-$0.35	9.09%	BEAT
Q1 '25	-$0.45	-$0.29	35.81%	BEAT
Q4 '24	-$0.56	-$0.48	15.04%	BEAT
Q3 '24	-$0.52	-$0.50	3.85%	BEAT

TARA
Protara Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q3 '25

Historical Earnings

Latest TARA News

TARA Protara Therapeutics Inc